arrow
A

Anne Tierens

University Health Network and University of Toronto
H指数:37
被引数:3,762

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

儿童急性髓系白血病(AML)的诊断与管理:国际专家小组的共识建议

Blood
IF23.1
2025-10-220
PRE
Don´t Fly and Freeze: Impact of Ex Vivo Time, Cell Density and Cryopreservation on Allogeneic Stem Cell Grafts

不要飞行和冷冻:异体干细胞移植中离体时间、细胞密度和冷冻保存的影响

2025-09-190
PRE
Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNXI::RUNXITI

在携带RUNXI::RUNXITI的急性髓系白血病儿童中,诱导期间出现白血病相关的具有非典型免疫表型的嗜碱性粒细胞和肥大细胞,不应被解释为可测量的微小残留病。

BLOOD
IF23.1
2024-11-050
PRE
Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol
2024-05-090
OAAI
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN

在加速和爆炸阶段MPN中强化和非强化爆炸减少策略的结果

2024-03-043
OAAI
Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia

DDX41活性的双等位基因破坏与急性白血病中不同的基因组和免疫表型标志相关

2023-06-264
OAAI
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
LEUKEMIA
IF13.4
2020-12-1428
OAAI
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
2020-05-0739
OAAI
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia (vol 33, pg 1324, 2020)
LEUKEMIA
IF13.4
2019-12-100
OAAI
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

白血病前期突变及其持续性对AML诱导化疗后血液学恢复的影响

2019-08-0115
OA